Through OIDD, Lilly has established a network of top global research talent at academic and biotech institutions to provide them access to proprietary, in vitro phenotypic and target-based assays (PD2 and TargetD2). This partnership is supported by the program’s website portal and application, which lowers the barrier for collaborations between investigators working inside and outside the Lilly walls. Although ChemAxon tools have been foundational to this project from the start, recently Lilly has been partnering with ChemAxon to deliver additional design and property tools for OIDD investigators to use as part of this initiative.
The Lilly Open Innovation Drug Discovery Program (OIDD)
Posted by
Daniel Robertson
on 13 09 2013
Related content
30 08 2022
< 1 minute
Key Properties in Drug Design | Predicting Lipophilicity, pKa and Solubility
PhysChem properties are key descriptors in drug design Lipophilicity, pKa and solubility are key...
13 07 2022
< 1 minute
Local and Global Models For Predicting Properties of Small Molecules
Which type of model has the most potential for success? The obvious answer is all models that are...
13 07 2022
< 1 minute
ICCS 2022 - Translating data to predictive models
Biological, chemical and physical properties of molecules are encoded in their molecular structure....
13 04 2022
< 1 minute
Efficient biomolecular structural data handling and analysis - Webinar with Discngine
Presenters: Peter Schmidtke- Product Manager, Discngine Márk Somogyi- Product Manager, Chemaxon...